GROUP
March 24th, 2021
PME featuring our latest Science Advances paper.
A collaborative effort together with the Hubbell group, our study introduces the potential of lymphangiogenesis induction as a novel immunotherapeutic strategy to consider in cancer vaccine design.
For the whole story please go to
https://advances.sciencemag.org/content/7/13/eabe4362
For the feature please go to
https://pme.uchicago.edu/news/exploiting-cancer-cells-aid-their-own-destruction
October 19th, 2020
Melody Swartz elected to
the National Academy of Medicine
Our very own Melody Swartz has been elected to the National Academy of Medicine.
The good news is featured by the Pritzker School of Molecular Engineering and online:
-
Facebook: https://www.facebook.com/UChicagoPME/posts/3340473442714457
-
LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:6723980456770990080
-
Twitter: https://twitter.com/UChicagoPME/status/1318215241336016896
-
Instagram: https://www.instagram.com/p/CGh83YZFwnW/
-
Faculty accolades page: https://pme.uchicago.edu/about/faculty-accolades
June 22nd-24th 2020
AACR 2020
It is good to check in with our collaborators around the globe at the annual meeting of the American Association for Cancer Research.
Due to Covid19 this years meeting is virtual and registration is free.
Getting a closer look at our latest work has never been easier.
Watch a presentation by Melody Swartz
on June 24, 2020 at 2:15 PM U.S. EDT,
Session MW12 - Emerging Models: Bring in the Engineers
"In vitro models of the tumor-immune interface".
AACR 2020
Our very own Nick, Maria Stella and Peyman have presented their latest findings at AACR online.
For more information click on their abstracts.
Immune Mechanisms Invoked by Therapies 2
June 22, 2020, 9:00 AM - 6:00 PM
2253 / 6 - Lymphangiogenesis augments the anti-tumor efficacy of radiotherapy in mouse melanoma
By Nick Mitrousis
Immunomodulatory Agents and Interventions
June 23, 2020, 9:20 AM - 9:30 AM
1072 - Lymphangiogenesis-inducing vaccines for melanoma treatment elicit potent tumor-specific T cell immunity and long-term tumor control
By Maria Stella Sasso
Novel Immunotherapies and Mechanisms
June 23, 2020, 9:20 AM - 9:30
5695 Induction of lymphangiogenesis in breast cancer enhances responsiveness to immunotherapies
By Peyman Hosseinchi
June 12th, 2020
CIIC featuring our latest nature paper.
A collaborative effort together with the Sperling group, our study investigates the role of pro-lymphangiogenic VEGFR-3 signaling in allergic airway inflammation.
For the whole story please go to
https://www.nature.com/articles/s41385-020-0308-4
May 26th, 2020
Chicago Maroon discusses PME Covid Resesearch
Research at the CIIC includes cancer immunotherapy and therapies for fruit allergies. But recently, the CIIC has focused a large effort toward COVID-19 research. Currently, there are projects for creating a vaccine for the disease led by Jeffrey Hubbell and Melody Swartz, co-directors of the center.
“The vaccine projects harmoniously bring together the resources of Pritzker School of Molecular Engineering and medical centers across the country,” Hubbell said.
To read the article please follow the link below.
https://www.chicagomaroon.com/article/2020/5/27/immunoengineering-center-investigates-covid-19-vac/
April 24th, 2020
Congratulations to our Nick Mitrousis, PhD.
Nick's innovative work on exploring the role of lymphangiogenesis
in the anti-tumor immune response to radiotherapy
is being supported by the CIHR's postdoctoral fellowship.
